B-MS breaking new ground with China's first I-O therapy

15 June 2018

Bristol-Myers Squibb (NYSE: BMY) has announced that the Chinese National Drug Administration (CNDA) has approved Opdivo (nivolumab) for lung cancer patients, the first immuno-oncology (I-O) therapy ever to be approved in the country.

Opdivo, along with Merck & Co's (NYSE: MRK) Keytruda, has been one of the leaders of the first wave of the I-O revolution, and its fast-growing sales were nearly $5 billion in 2017.

"Lung cancer is a major public health issue in China, representing the highest incidence and mortality among all cancers in the country," said Yi-Long Wu, director of Guangdong hospital and chairman of the Chinese Thoracic Oncology Group. "With most lung cancer patients already at an advanced stage when diagnosed, prolonging survival is an important goal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK